CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5 enrolled
Drug / intervention
Tafamidisdrug
Likely dose
Tafamidis 61 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05560555
NCT05560555N/ACompleted
CompareCT.gov

Tafamidis 61mg, Outcomes in ATTR Amyloidosis With Neurologic and Multisystemic Involvement - TRAMA

Pfizer·observational·Posted Sep 29, 2022·Updated May 13, 2024

In Brief

An observational study evaluating Tafamidis for Hereditary Transthyretin Amyloidosis (ATTRv) and Polyneuropathy. Completed, enrolled 5 participants across 3 sites.

Detailed Summary

A study of patients with hereditary transthyretin amyloidosis (ATTRv) and wild-type transthyretin amyloidosis (ATTRwt) that have been enrolled in B3461028 and B3461045 studies in Spain - exposed to tafamidis 61mg for ≥12 months with polyneuropathy (PN) have kept going to their multisystemic follow-ups (neuro/ophthalmo/gastrointestinal) ≥12 months.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Transthyretin Amyloidosis (ATTRv), Polyneuropathy
CountriesSpain
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedSep 29, 2022
Enrollment StartOct 24, 2022
Primary CompletionNov 15, 2022
TodayJul 2, 2026
Enrollment to primary: 21 daysPosted 3.8 years ago

Interventions

Tafamidisdrug

61 milligrams (mg) as received in studies B3461028 and B3461045